製品の概要

  • 製品名Anti-FGFR1 (phospho Y654) antibody
    FGFR1 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to FGFR1 (phospho Y654)
  • 特異性Binds human and mouse FGFR1 only when phosphorylated at tyrosine 654 and rat FGFR1 only when phosphorylated at tyrosine 561.
  • アプリケーション適用あり: IHC-P, ICC/IF, WB, ELISAmore details
  • 種交差性
    交差種: Mouse, Rat, Human
  • 免疫原

    Synthetic phosphopeptide (Human) from around the phosphorylation site of tyrosine 654 (DYYPKK)

  • ポジティブ・コントロール
    • This antibody gave a positive signal in SKNSH cell line in ICC/IF. This antibody gave a positive result in IHC in the following FFPE tissue: Human breast adenocarcinoma.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab59194 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF Use a concentration of 5 µg/ml.
WB 1/500 - 1/1000. Detects a band of approximately 117 kDa (predicted molecular weight: 92 kDa).
ELISA 1/20000.

ターゲット情報

  • 機能Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF).
  • 組織特異性Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells.
  • 関連疾患Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
    Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
    Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
    Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
    Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
    Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity.
  • 配列類似性Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
    Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • 翻訳後修飾Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor.
  • 細胞内局在Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle
  • Information by UniProt
  • 参照データベース
  • 別名
    • Basic fibroblast growth factor receptor 1 antibody
    • bFGF-R-1 antibody
    • BFGFR antibody
    • CD331 antibody
    • CEK antibody
    • FGFBR antibody
    • FGFR 1 antibody
    • FGFR-1 antibody
    • FGFR1 antibody
    • FGFR1/PLAG1 fusion antibody
    • FGFR1_HUMAN antibody
    • fibroblast growth factor receptor 1 antibody
    • FLG antibody
    • FLT-2 antibody
    • FLT2 antibody
    • Fms-like gene antibody
    • Fms-like tyrosine kinase 2 antibody
    • fms-related tyrosine kinase 2 antibody
    • HBGFR antibody
    • heparin-binding growth factor receptor antibody
    • HH2 antibody
    • HRTFDS antibody
    • hydroxyaryl-protein kinase antibody
    • KAL2 antibody
    • N-SAM antibody
    • OGD antibody
    • Proto-oncogene c-Fgr antibody
    see all

Anti-FGFR1 (phospho Y654) antibody 画像

  • IHC image of FGFR1 (phospho Y654)  staining in Human breast adenocarcinoma formalin fixed paraffin embedded tissue section, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab59194, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

     

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • All lanes : Anti-FGFR1 (phospho Y654) antibody (ab59194) at 1/500 dilution

    Lane 1 : 293 cell extract treated with insulin (0.01U/ml, 15 mins)
    Lane 2 : 293 cell extract treated with insulin (0.01U/ml, 15 mins) with immunizing phosphopeptide


    Predicted band size : 92 kDa
    Observed band size : 120 kDa (why is the actual band size different from the predicted?)
  • ICC/IF image of ab59194 stained SKNSH cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab59194, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
  • Immunofluorescent analysis of COS7 cells labeling FGFR1 (phospho-Tyr654 with ab59194 at 1:100. The image on the right is blocked with the phosphopeptide prior to imunnoflurescent labeling.

Anti-FGFR1 (phospho Y654) antibody (ab59194) 使用論文

This product has been referenced in:
  • Schwenk BM  et al. TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO J 35:2350-2370 (2016). Read more (PubMed: 27621269) »
  • Knelson EH  et al. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest 124:3016-31 (2014). WB . Read more (PubMed: 24937430) »

See all 4 Publications for this product

Product Wall

For diluting these antibodies for western blotting, we recommend PBS, 0.1% Triton X-100, with 1% BSA.

Thank you for contacting us.

I have conducted a search through our catalogue for antibodies against pFGFR1 and pFGFR4 which do no cross-react with the other FGFRs.

Ab59180 is specific against FGFR1 when it is phosphorilated at Tyr76...

Read More

Thank you for contacting us.

I have received the following information from the lab:

1) This antibody reacts with target strongly when target is phosphorylated only on Y654 (phospho-Y654).
2) This antibody has weak reaction wi...

Read More

I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has caused. As requested, I have issued a free of charge replacement for one vial of ab59194. To check the status of the order please contact our C...

Read More

Thank you for contacting us. Indeed, crossreactivity is always a very important information for an antibody. Sequence alignment and experimental data can help to predict/determine this. We receive these antibodies from a collaborating l...

Read More

Thank you for contacting us. The protocol is as follows: a. 293 cells were plated on flask or dishes containing growth medium (basic medium containing 10% serum). b. When the cells were at the log phase and 80-90% confluent, the culture media w...

Read More

Thank you for your enquiry and your interest in our products. I have discussed your enquiry with my colleagues in the Lab and we think the antibody can detect both endogenous FGFR1 (phospho Y654) and the induced/stimulated FGFR1 at this modification...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"